Agile Therapeutics Inc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Agile Therapeutics Inc (AGRX) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Agile Therapeutics Inc vs Its Competitors
- TTM: Trailing 12-month revenue of 20M vs 155,484M combined for tracked competitors (0.0% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+3.0% annualized vs trailing 12 months), vs decelerating (-23.6%) for its tracked peer group.
- Growth: Agile Therapeutics Inc generated -2.2% revenue growth year over year in Q2 2024, vs 18.3% for its tracked competitors combined.
- Profitability: Its -233.7% net margin compares with 8.1% for the peer group.
- Peer revenue share: Agile Therapeutics Inc accounted for 0.0% of combined revenue among its tracked peer group, up from 0.0% a year earlier.
- Peer differentiation: Revenue per employee of $1.04M compares with $1.08M for the peer group (1.0x).
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
AGRX Sales vs. its Competitors, Q2 2024
Agile Therapeutics Inc reported revenue contraction of 2.23 % year on year in Q2 2024, below its competitors' combined revenue growth of 18.26 %.
With a net margin of -233.70 %, Agile Therapeutics Inc reported lower profitability than its competitors (8.12 %).
Agile Therapeutics Inc generated 0.02 % of the combined sales of its peer group, up from 0.02 % a year earlier.
Agile Therapeutics Inc vs. its Competitors, Q2 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Agile Therapeutics Inc and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Agile Therapeutics Inc | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| High-Confidence Competitors (4) | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (5) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Agile Therapeutics Inc's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -2.2% for Agile Therapeutics Inc. Agile Therapeutics Inc's share of combined industry revenue moved from 0.00% to 0.00%, a gain of 0.00 percentage points.
Agile Therapeutics Inc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Agile Therapeutics Inc | No | Yes | Yes | No |
| Competitors combined (13) | ||||
| High-Confidence Competitors (6) | ||||
| Similar Growth & Profitability (8) | 25.00 % (2 of 8) | 75.00 % (6 of 8) | 62.50 % (5 of 8) | 0.00 % (0 of 6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
AGRX Stock Performance relative to its Competitors
AGRX Stock Performance relative to High-Confidence Competitors
AGRX Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Teva Pharmaceutical Industries Limited | 282.9% | Outperformed |
| 2 | Amneal Pharmaceuticals Inc | 282.9% | Outperformed |
| 3 | Puma Biotechnology Inc | 282.9% | Outperformed |
| 4 | Therapeuticsmd Inc | 282.9% | Outperformed |
| 5 | Viatris Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Agile Therapeutics Inc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Agile Therapeutics Inc's Comment on Competition and Industry Peers
Publicly Traded Peers of Agile Therapeutics Inc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Agile Therapeutics Inc | 10.35 | 19.72 |
| Eli Lilly And Company | 1,058,837.89 | 79,665.80 |
| Amgen Inc | 227,462.72 | 38,095.00 |
| Teva Pharmaceutical Industries Limited | 45,295.20 | 14,105.00 |
| Viatris Inc | 21,253.49 | 14,737.30 |
| Amneal Pharmaceuticals Inc | 6,726.09 | 3,117.47 |
| SUBTOTAL | 1,373,890.55 | 155,883.22 |
Sign in to see all competitors of Agile Therapeutics Inc.
Sources: Agile Therapeutics Inc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Agile Therapeutics Inc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Agile Therapeutics Inc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Bayer | Named by the company | 85% |
| Mithra Pharmaceuticals | Named by the company | 85% |
| Viatris | Named by the company | 85% |
| Actavis | Named by the company | 85% |
| Mayne Pharmaceuticals | Named by the company | 85% |
| Population Council | Named by the company | 85% |
| Corium Innovations, Inc. | Named by the company | 85% |
| Mylan | Named by the company | 85% |
| Allergan | Named by the company | 85% |
| Merck | Named by the company | 85% |
| Therapeutics MD | Named by the company | 85% |
| Evofem | Named by the company | 85% |
| Organon | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Agile Therapeutics Inc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Agile Therapeutics Inc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Eli Lilly And Company | Reportable 100.00 % |
| Amgen Inc | Reportable 100.00 % |
| Teva Pharmaceutical Industries Limited | United States Segment 41.09 % |
| Viatris Inc | Developed Markets 57.61 % |
| Amneal Pharmaceuticals Inc | Affordable Medicines 58.61 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Sign in to see all peers for Agile Therapeutics Inc.
Agile Therapeutics Inc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Agile Therapeutics Inc | 10 | 1,038,000 | -834,421 |
| Eli Lilly And Company | 1,058,838 | 1,593,316 | 534,224 |
| Amgen Inc | 227,463 | 2,930,385 | 672,538 |
| Teva Pharmaceutical Industries Limited | 45,295 | 415,464 | 20,884 |
| Viatris Inc | 21,253 | 491,243 | -13,690 |
| Amneal Pharmaceuticals Inc | 6,726 | 366,762 | 25,332 |
| PEERS TOTAL | 1,373,880 | 1,075,247 | 235,786 |
Sign in to see all peers for Agile Therapeutics Inc.
Agile Therapeutics Inc's Geographic Revenue Exposure vs Peers
Revenue by country/region as reported in each company's most recent filing. Disclosure granularity varies by filer (some report by country, others by broad region) and is shown as disclosed.| Company | Largest Market |
|---|---|
| Eli Lilly And Company | United States 61.21 % |
| Teva Pharmaceutical Industries Limited | Europe 30.49 % |
| Perrigo Company Plc | United States 57.24 % |
| Therapeuticsmd Inc | Non Us 66.30 % |
Source: revenue geography as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API. Percentages are of that company's own total consolidated revenue for its most recent reported period.
Agile Therapeutics Inc's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | 69.59 % | 64.89 % (avg) | +4.7 pp |
| Operating Margin | -68.72 % | industry median | +28.0 pp |
| EBITDA Margin | -74.14 % | -7.21 % (avg) | -66.9 pp |
| Capital Intensity (Capex / Revenue) | - | 4.92 % (avg) | - |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Agile Therapeutics Inc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | -0.4x | 4.5x | -4.8x |
| Return on Equity | 104.02 % | industry aggregate | 91.70 % |
| Return on Invested Capital | 55.19 % | -2.95 % (avg) | 58.14 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Agile Therapeutics Inc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2016 | 2017 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - | 165.40 % | 71.03 % |
| Operating Margin | - | - | - | - | -1,731.41 % | -482.87 % | -106.82 % |
| Return on Invested Capital | -26.34 % | -34.77 % | -30.05 % | -30.78 % | -136.47 % | -953.74 % | 106.05 % |
| P/E | - | - | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Agile Therapeutics Inc's Strategic Group Map
Every company in Agile Therapeutics Inc's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Agile Therapeutics Inc is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Agile Therapeutics Inc's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Agile Therapeutics Inc falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Agile Therapeutics Inc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 28.0 points above the industry median.
- Return on equity 91.7 points above the industry aggregate.
- Latest-quarter revenue run-rate is accelerating (+3.0% annualized vs trailing 12 months).
Weaknesses
No rule matched.
Opportunities
No rule matched.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-23.6% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Agile Therapeutics Inc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Agile Therapeutics Inc | 0.13 | 0.54 | - |
| Eli Lilly And Company | 0.20 | 1.48 | 1.59 |
| Amgen Inc | 0.46 | 1.26 | 5.86 |
| Teva Pharmaceutical Industries Limited | 0.24 | 1.00 | 2.15 |
| Viatris Inc | 0.18 | 1.47 | 0.96 |
| Amneal Pharmaceuticals Inc | 0.26 | 2.23 | - |
Sign in to see all peers for Agile Therapeutics Inc.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Agile Therapeutics Inc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Agile Therapeutics Inc | Q2 2024 | -2.2 % | - |
| Eli Lilly And Company | Q2 2026 | +47.7 % | +25.3 % |
| Amgen Inc | Q2 2026 | +9.5 % | +65.9 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -0.8 % | - |
| Viatris Inc | Q2 2026 | +4.9 % | - |
| Amneal Pharmaceuticals Inc | Q2 2026 | +9.9 % | +95.5 % |
| PEERS TOTAL | +24.9 % | +21.1 % |
Sign in to see all peers for Agile Therapeutics Inc.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Agile Therapeutics Inc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Agile Therapeutics Inc | Q2 2024 | -1.2 % | - |
| Eli Lilly And Company | Q2 2026 | +33.5 % | +72.8 % |
| Amgen Inc | Q2 2026 | -6.6 % | +39.0 % |
| Teva Pharmaceutical Industries Limited | Q2 2026 | -4.1 % | - |
| Viatris Inc | Q2 2026 | +2.3 % | -0.2 % |
| Amneal Pharmaceuticals Inc | Q2 2026 | +5.4 % | +354.5 % |
Sign in to see all peers for Agile Therapeutics Inc.
Agile Therapeutics Inc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Agile Therapeutics Inc | - | - | - |
| Eli Lilly And Company | 21.97% | 33.95% | 92.54% |
| Amgen Inc | 9.48% | 13.08% | 89.32% |
| Teva Pharmaceutical Industries Limited | 1.77% | 2.66% | 9.11% |
| Viatris Inc | - | - | - |
| Amneal Pharmaceuticals Inc | 5.90% | 7.91% | - |
Sign in to see all peers for Agile Therapeutics Inc.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Agile Therapeutics Inc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Agile Therapeutics Inc | - | 0.52 |
| Eli Lilly And Company | 39.77 | 13.29 |
| Amgen Inc | 25.97 | 5.97 |
| Teva Pharmaceutical Industries Limited | 63.88 | 3.21 |
| Viatris Inc | - | 1.44 |
| Amneal Pharmaceuticals Inc | 41.84 | 2.16 |
| PEERS AVERAGE | 40.22 | 8.81 |
Sign in to see all peers for Agile Therapeutics Inc.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.